Navigation Links
Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
Date:4/7/2009

- New offices in Chile and Peru, expansion of Argentina office increase access to patients to reduce drug development timelines for biopharmaceutical companies -

PRINCETON, N.J., April 7 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced the recent opening of new clinical development offices in Santiago, Chile, and Lima, Peru, and the expansion of the company's Buenos Aires, Argentina office. These latest office openings further extend the company's global clinical development presence to increase patient access and reduce clinical development timelines.

Covance has been providing clinical trial support in Latin America since 1997 with the company's first office in Buenos Aires, Argentina. Operations in Latin America expanded quickly with the organization of an extensive and highly-trained network of regional clinical trial monitors. The new clinical offices located in Santiago and Lima will support staff in Chile and Peru, including Covance's regional network of field-based clinical research associates throughout Latin America.

"Our strategy is to target areas for qualified patient populations and the most qualified investigators as we selectively expand our presence in key metropolitan centers in emerging regions such as Latin America," said Katie Margules, Covance's senior director of project management in Latin America. "Our focus continues to be on delivering outstanding drug development and building stronger strategic relationships with our clients."

The new offices and expanded facilities in Latin America will help Covance expedite the execution of clinical studies with a full range of services, and build strategic relationships with investigators, sites, and regulatory authorities in a region known for its strong potential to contribute to high-quality global clinical trial conduct.

"We are committed to continuing to build our infrastructure across Latin America, expanding current facilities, and opening further new clinical offices to increase Phase III clinical trial productivity," said Wayne Langlois, Covance's vice president and general manager of clinical development services, Americas. "These countries offer qualified patient populations and investigators which help reduce clinical development timelines for our biopharmaceutical clients."

Covance offers clinical development services, including Phase I to IV clinical trial support in more than 55 countries which include emerging markets across Asia Pacific, Central and Eastern Europe, and Latin America. With a full-suite of services to take a drug through all stages of drug development, Covance offers extensive clinical and therapeutic expertise, global reach, proactive project management, and strong investigator site relationships to consistently deliver high quality data on time.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 25 countries, and more than 9,600 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
2. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
3. Covance Purchases Equity Stake in Caprion Proteomics
4. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
5. Covance Decides to Pursue Its Original Preclinical Strategy in China
6. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
7. Covance to Present at The R.W. Baird 2008 Growth Stock Conference
8. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
10. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
11. Cells Exhibition Opens at Maryland Science Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... , ... Dr. Asher Kimchi, Founder and Chairman of the International Academy ... the 22nd World Congress on Heart Disease held in Vancouver, BC, Canada. In addition ... Fellowship Awards. , Dr. Asher Kimchi, together with Co-Chairmen Dr. John A. Elefteriades and ...
(Date:7/20/2017)... , ... July 20, 2017 , ... VIC Technology ... joining the company’s board of directors. This addition continues to strengthen and diversify ... Calvin Goforth, CEO and Chairman. “He is a highly accomplished business executive with a ...
(Date:7/20/2017)... 20, 2017   KCNQ2 Cure Alliance  and ... company, today announced that they have completed the ... mutation implicated in KCNQ2 epileptic encephalopathy. They also ... second case involving an additional KCNQ2 genetic mutation. ... and Pairnomix entered into a collaboration to further ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... solution to make clinical trial sites and study participants truly unified. TrialKit, a ... compliant (FDA 21 CFR Part 11) research studies entirely on mobile devices. With ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):